Physician profile
Abeera Mansur
NPI 1033541610
$800.92
in general payments reported to CMS, 2019-2025
17 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.19 · 2022: $140 · 2023: $207 · 2024: $234 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570 · Education: $75.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.04 |
| Education | $75.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $110.74 | 2022-2024 | Jynarque |
| Fresenius USA Marketing, INC. | $108.77 | 2024-2025 | Velphoro, Velphoro |
| Amgen INC. | $102.66 | 2023-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $89.69 | 2023-2024 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $66.63 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $46.85 | 2020-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $43.37 | 2025 | |
| Vifor Pharma, INC. | $42.97 | 2022-2023 | Veltassa |
| Novartis Pharmaceuticals Corporation | $31.99 | 2022-2025 | |
| Medtronic, INC. | $27.29 | 2025 | Symplicity G3 |
| Horizon Therapeutics Plc | $21.66 | 2022 | |
| Abbott Laboratories | $21.58 | 2024 | Cardiomems |
| Scpharmaceuticals INC. | $19.11 | 2024 | |
| Lilly USA, LLC | $17.69 | 2022 | |
| Glaxosmithkline, LLC. | $17.60 | 2025 | Shingrix, Arexvy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.34 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $14.98 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abeera Mansur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.